Skip to content

First in human, Phase 1a/1b Study of KM-023 in healthy volunteers and Olmsted syndrome patients

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-521446-20-00
Acronym
KM023-101
Enrollment
64
Registered
2025-06-25
Start date
2025-06-27
Completion date
Unknown
Last updated
2025-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Olmsted syndrome

Interventions

None listed

Sponsors

Kamari Pharma Ltd.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026